Perennial Allergic Rhinitis Clinical Trial
— PAROfficial title:
A Phase III, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Efficacy and Safety of Probiotics eN-Lac® Capsules (Lactobacillus Paracasei GMNL-32) for the Treatment of Children With Perennial Allergic Rhinitis
The purpose of this study is to evaluate the efficacy and safety of probiotics eN-Lac® capsules (Lactobacillus paracasei GMNL-32) for the treatment of children with perennial allergic rhinitis(PAR).
Status | Completed |
Enrollment | 236 |
Est. completion date | June 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 5 Years to 16 Years |
Eligibility |
Inclusion Criteria - Subjects in age of 5-16 years old - Subjects with a history of perennial allergic rhinitis for at least 1 year. - Subjects with anyone of the following allergy test results (test results within 12 months before study are acceptable) - Skin-Prick test: Wheal diameter 3 mm larger than the negative control (salt water) and at least 1/2 the diameter of the positive control (histamine) - Positive reaction determined by the CAP system Positive reaction defined as CAP score=2 - Positive reaction determined by the MAST system Positive reaction defined as MAST score=1 - Subject's mean nasal total symptom score (NTSS) throughout the screening period (4 to 10 days) should be = 5 and = 10; at least 3 days should be recorded during the screening period - Subjects' parents or their legally acceptable representatives have signed the informed consent form. Exclusion Criteria - Subjects have clinically significant laboratory abnormality results (hematology, biochemistry or urinalysis tests) as determined by the investigator (tests performed during 14 days prior to visit 1 or during baseline period can be used for evaluating those criteria). - Subjects with acute or significant chronic sinusitis, severe persistent asthma, congenital immunodeficiency, massive wound in oral cavity, use of rhinitis medications, neuropsychiatric disorders, immunocompromised, or chronic use of tricyclic antidepressants. - Subjects need to take prohibited medications during the study or take the medications within the corresponding time frame indicated prior to the screening visit: Parenteral or oral corticosteroids 30 days Nasal corticosteroids 30 days Topical use of flurandrenolide 30 days Topical use of clobetasol propionate 30 days Topical use of halobetasol propionate 30 days Astemizole 30 days Ketotifene 21 days Nedocromil or Sodium cromoglycate 14 days Loratadine 10 days Cetirizine 7 days Antileukotrienes 7 days Other H1 antihistamine 3 days Nasal decongestant 3 days Any food supplements including probiotics 3 days - Subjects are undergoing desensitization therapy within 3 months prior to the screening period or subjects with vasomotor rhinitis. - Subjects have participated investigational drug trial within 4 weeks before entering this study. - Subjects are pregnant, lactating or planning to become pregnant. - Subjects with any other serious diseases considered by the investigator that could interfere with the performance of NTSS result. - Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period. - Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Children's Hospital | Taipei | |
Taiwan | MacKay Memorial Hospital | Taipei | |
Taiwan | Taipei City Hospital Renai Branch | Taipei | |
Taiwan | Cardinal Tien Hospital | Xindian | Taipei |
Lead Sponsor | Collaborator |
---|---|
GenMont Biotech Incorporation | Biomedical Development Corporation |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the efficacy profile of probiotics Lactobacillus paracasei GMNL-32 (eN-Lac®) in children with perennial allergic rhinitis. | NTSS is determined by the severity of allergic symptoms, including sneezing, rhinorrhea, nasal itching, and nasal stuffiness. These symptoms are evaluated using a four-point scale, namely, 0 = Absent, 1 = Mild (present but not disturbing), 2 = Moderate (disturbing but not hampering daytime activities and/or sleep), 3 = Severe (hampering daytime activities and/or sleep). NTSS is calculated by the sum of the scores of the symptoms. | NTSS is recorded daily on subject's DRC (daily record card) at the 8th week from baseline. | No |
Secondary | The safety features are evaluated through the changes of vital signs, physical examinations, laboratory test result (hematology, biochemistry and urinalysis tests), as well as the occurrence of adverse event. | The incidence of adverse events will be categorized by severity and related to the time of occurrence. Changes in physical examinations, changes in laboratory test results (hematology, biochemistry and urinalysis tests) from screening period, and change of vital signs will be summarized and analyzed by the descriptive statistics. | at 8th week from basline | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01654536 -
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
|
Phase 4 | |
Completed |
NCT01539304 -
Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT01221285 -
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
|
Phase 1 | |
Terminated |
NCT00491374 -
Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)
|
Phase 4 | |
Completed |
NCT00783224 -
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
|
Phase 3 | |
Completed |
NCT04324918 -
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT02532179 -
Subcutaneous Immunotherapy for Mouse in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01451541 -
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
|
Phase 3 | |
Enrolling by invitation |
NCT01062139 -
Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy
|
Phase 4 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT01549340 -
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
|
N/A | |
Completed |
NCT01018862 -
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00789555 -
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00261287 -
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
|
Phase 3 | |
Completed |
NCT00974571 -
Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
|
Phase 3 | |
Completed |
NCT04654702 -
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
|
||
Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
Completed |
NCT01380327 -
Biomarkers of Cockroach Sublingual Immunotherapy 2
|
Phase 1/Phase 2 | |
Completed |
NCT00359216 -
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
|
Phase 4 | |
Completed |
NCT01127620 -
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
|
Phase 3 |